Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 13%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group is well-positioned for success in the biotechnology space, with a strong focus on developing innovative oncolytic immunotherapies for the treatment of cancer. The company's proprietary RPx platform, which utilizes a herpes simplex virus backbone, has shown great promise in activating the immune system against solid tumors. Additionally, the company's majority revenue from the USA highlights their potential for growth and success in the largest healthcare market in the world.

Bears say

Replimune Group is facing numerous challenges with its RPx platform, as the FDA has continuously raised concerns about the efficacy and validity of its clinical data for RP1. These include difficulty isolating the contributions of RP1 when administered with nivolumab, heterogeneity of the patient population, and lack of a well-established historical control. This has led to delays and uncertainty in the drug's path to market and has sparked a need for potential restructuring. As a result, financial success for Replimune Group is at risk, and the likelihood of RPx platform's success and commercialization is uncertain.

REPL has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 13% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Hold based on their latest research and market trends.

According to 8 analysts, REPL has a Hold consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.